Syncope is a sudden and generally momentary loss of consciousness, which can have serious adverse events. The outcomes of the syncope episode can vary from a fall to fatal accidents. Syncope has a major negative effect on the patient's health-related quality of life. The economic burden of syncope on healthcare systems is considerable. There are no clear diagnostic pathways for identifying the cause of syncope; patients can be admitted to hospital and undergo expensive and often repeated and inconclusive diagnostic tests. Implantable cardiac monitors have been available for more than a decade to help early diagnosis of syncope in unexplained cases. However, despite being a Canadian invention, the use of the implantable cardiac monitors has been suboptimal in the Canadian healthcare system. This study provides an overview of syncope, its management, and presents the estimated potential cost savings per diagnosis of systematic use of implantable cardiac monitors in Ontario.
Get full access to this article
View all access options for this article.
References
1.
BrignoleMAlboniPBendittDG. Guidelines on management (diagnosis and treatment) of syncope. Europace2004; 6(6): 467–537.
2.
SoteriadesESEvansJCLarsonMGChenMHChenLBenjaminEJ. Incidence and prognosis of syncope. N Engl J Med2002; 347(12): 878–885.
3.
SilversteinMDSingerDEMulleyAGThibaultGEBarnettGO. Patients with syncope admitted to medical intensive care units. J Am Med Assoc1982; 248(10): 1185–1189.
4.
FarwellDJSulkeAN. Does the use of a syncope diagnostic protocol improve the investigation and management of syncope?Heart2004; 90(1): 52–58.
5.
FarwellDSulkeN. How do we diagnose syncope?J Cardiovasc Electrophysiol2002; 13(suppl): S9–S13.
6.
MiddlekauffHRStevensonWGStevensonLWSaxonLA. Syncope in advanced heart failure: High risk of sudden death regardless of origin of syncope. J Am Coll Cardiol1993; 21 (1): 110–116.
7.
BrignoleM. International study on syncope of uncertain aetiology: Pacemaker therapy for patients with asystolic neurally-mediated syncope: Rationale and study design. Europace2007; 9(1): 25–30.
8.
LeeSMOhHLKimJSYimHRShinDHLeeSH. Comparison of recurrence rate based on the frequency of preceding symptoms in patients with neurocardiogenic syncope or presyncope. Korean Circ J2011; 41(8): 434–439.
FitzpatrickAPCooperP. Diagnosis and management of patients with blackouts. Heart2006; 92(4): 559–568.
14.
AlshekhleeAShenWKMacKallJChelimskyTC. Incidence and mortality rates of syncope in the United States. Am J Med2009; 122(2): 181–188.
15.
LinzerMYangEHEstesNA. Diagnosing syncope: Part 1: Value of history, physical examination, and electrocardiography. The clinical efficacy assessment project of the American College of Physicians. Ann Intern Med1997; 126(12): 989–996.
16.
BergfeldtL. Differential diagnosis of cardiogenic syncope and seizure disorders. Heart2003; 89 (3): 353.
17.
FarwellDJFreemantleNSulkeN. The clinical impact of implantable loop recorders in patients with syncope. Eur Heart J2006; 27(3): 351–356.
18.
DisertoriMBrignoleMMenozziC. Management of patients with syncope referred urgently to general hospitals. Europace2003; 5(3): 283–291.
SheldonRSMorilloCAKrahnAD. Standardized approaches to the investigation of syncope: Canadian Cardiovascular Society position paper. Can J Cardiol2011; 27(2): 246–253.
21.
BrignoleMSuttonRMenozziC. Early application of an implantable loop recorder allows effective specific therapy in patients with recurrent suspected neurally mediated syncope. Eur Heart J2006; 27(9): 1085–1092.
22.
EdhagOSwahnA. Prognosis of patients with complete heart block or arrhythmic syncope who were not treated with artificial pacemakers. A long-term follow-up study of 101 patients. Acta Med Scand1976; 200(6): 457–463.
23.
GassMApitzCSalehi-GilaniSZiemerGHofbeckM. Use of the implantable loop recorder in children and adolescents. Cardiol Young2006; 16(6): 572–578.
24.
ArmstrongVLLawsonJKamperAMNewtonJKennyRA. The use of an implantable loop recorder in the investigation of unexplained syncope in older people. Age Ageing2003; 32 (2): 185–188.
25.
KapoorWN. Diagnostic evaluation of syncope. Am J Med1991; 90(1): 91–106.
26.
LinzerMPritchettELPontinenMMcCarthyEDivineGW. Incremental diagnostic yield of loop electrocardiographic recorders in unexplained syncope. Am J Cardiol1990; 66(2): 214–219.
27.
FitzpatrickAPLeeRJEpsteinLMLeshMDEisenbergSSheinmanMM. Effect of patient characteristics on the yield of prolonged baseline head-up tilt testing and the additional yield of drug provocation. Heart1996; 76 (5): 406.
28.
KrahnADKleinGJYeeRHochJSSkanesAC. Cost implications of testing strategy in patients with syncope: Randomized assessment of syncope trial. J Am Coll Cardiol2003; 42(3): 495–501.
29.
KrahnADKleinGJYeeRTakle-NewhouseTNorrisC. Use of an extended monitoring strategy in patients with problematic syncope. Reveal Investigators. Circulation1999; 99(3): 406–410.
30.
KrahnADKleinGJYeeRMandaV. The high cost of syncope: Cost implications of a new insertable loop recorder in the investigation of recurrent syncope. Am Heart J1999; 137(5): 870–877.
31.
HillsM. The psychological and social impact of epilepsy. Neurol Asia2007; 12(suppl 1): 10–12.
32.
ZaidiACloughPCooperPScheepersBFitzpatrickAP. Misdiagnosis of epilepsy: Many seizure-like attacks have a cardiovascular cause. J Am Coll Cardiol2000; 36(1): 181–184.
33.
RoseMSKoshmanMLSprengSSheldonR. The relationship between health-related quality of life and frequency of spells in patients with syncope. J Clin Epidemiol2000; 53(12): 1209–1216.
34.
LinzerMPontinenMGoldDTDivineGWFelderABrooksWB. Impairment of physical and psychosocial function in recurrent syncope. J Clin Epidemiol1991; 44(10): 1037–1043.
35.
Medical Services Advisory Committee. Implantable loop recorder for unexplained recurrent syncope. MSAC application 1061. 〈http://www.ag.gov.au/cca〉; 2003 Accesses December 2013.
36.
GuyattGCairnsJChurchillD. Evidence-based medicine. A new approach to teaching the practice of medicine. J Am Med Assoc1992; 268(17): 2420–2425.
37.
MenonDStafinskiT. Technology assessment in Canada: 20 years strong?Value Health2009; 12(suppl 2): S14–S19.
38.
BleichrodtHQuigginJ. Life-cycle preferences over consumption and health: When is cost-effectiveness analysis equivalent to cost-benefit analysis?J Health Econ1999; 18(6): 681–708.
39.
MortimerDSegalL. Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decis Making2007; 28(1): 66–89.
40.
MOHLTC. New Evidence-Based Changes to OHIP Services; 2011.
41.
ChengFYouJRampersaudR. Relationship between spinal magnetic resonance imaging findings and candidacy for spinal surgery. Can Fam Physician2012; 56 (11): 323.
42.
MorrisonA. Appropriate Utilization of Advanced Diagnostic Imaging Procedures: CT, MRI, and PET/CT [Environmental Scan, Issue 39]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2013.
43.
Implant rates of ICM in various countries. Medtronic communications 2013, data on file.
44.
DavisSWestbyMPitcherDPetkarS. Implantable loop recorders are cost-effective when used to investigate transient loss of consciousness which is either suspected to be arrhythmic or remains unexplained. Europace2012; 14(3): 402–409.
45.
KrahnADKleinGJYeeRHochJSSkanesAC. Cost implications of testing strategy in patients with syncope: Randomized assessment of syncope trial. J Am Coll Cardiol2003; 42(3): 495–501.
46.
CalkinsHByrneMel-AtassiRKalbfleischSLangbergJJMoradyF. The economic burden of unrecognized vasodepressor syncope. Am J Med1993; 95(5): 473–479.
47.
FarwellDJFreemantleNSulkeAN. Use of implantable loop recorders in the diagnosis and management of syncope. Eur Heart J2004; 25(14): 1257–1263.
48.
GiadaFGuliziaMFranceseM. Recurrent unexplained palpitations study comparison of implantable loop recorder versus conventional diagnostic strategy. J Am Coll Cardiol2007; 49(19): 1951–1956.
49.
Canadian Agency for Drugs and Technologies in Health. Health Technology Update. Issue 11; 2009.
50.
PronGIeraciLKaulbackK, Medical Advisory Secretariat, Health Quality Ontario. Internet-based device-assisted remote monitoring of cardiac implantable electronic devices: An evidence-based analysis. Ontario Health Technol Assess Ser2012; 12(1): 1–86.
